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This study addresses the hypothesis that altered expression of oestrogen receptor-beta and/or altered relative expression of
coactivators and corepressors of oestrogen receptors are associated with and may be mechanisms of de novo tamoxifen
resistance in oestrogen receptor positive breast cancer. All cases were oestrogen receptor +, node negative, primary breast
tumours from patients who later had no disease progression (tamoxifen sensitive) or whose disease progressed while on
tamoxifen (tamoxifen resistant). Using an antibody to oestrogen receptor-beta that detects multiple forms of this protein
(total) but not an antibody that detects only full-length oestrogen receptor-beta 1, it was found that high total oestrogen
receptor beta protein expressors were more frequently observed in tamoxifen sensitive tumours than resistant tumours
(Fisher’s exact test, P=0.046). However, no signiﬁcant differences in the relative expression of oestrogen receptor b2,
oestrogen receptor b5 and full-length oestrogen receptor b1 RNA in the tamoxifen sensitive and resistant groups were found.
Also, when the relative expression of two known coactivators, steroid receptor RNA activator and ampliﬁed in breast cancer
1 RNA to the known corepressor, repressor of oestrogen receptor activity RNA, was examined, no signiﬁcant differences
between the tamoxifen sensitive and resistant groups were found. Altogether, there is little evidence for altered coregulators
expression in breast tumours that are de novo tamoxifen resistant. However, our data provide preliminary evidence that the
expression of oestrogen receptor b protein isoforms may differ in primary tumours of breast cancer patients who prove to
have differential sensitivity to tamoxifen therapy.
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The ability of anti-oestrogens such as tamoxifen to compete with
oestrogens for binding to OR and to antagonise their mitogenic
action provides the basic rationale for endocrine therapy and
prevention (for a review see (Osborne, 1998b) in breast cancer.
Adjuvant tamoxifen post-operative therapy reduces the number
of recurrences and prolongs survival in women whose primary
tumours are oestrogen receptor (OR) positive (Group, 1998).
However, even though OR level is considered a marker for
predicting the likelihood of responding to adjuvant hormonal
therapies, some patients, whose primary tumours are OR positive
do not respond to tamoxifen treatment. Such apparent de novo
tamoxifen resistance does not depend upon the level of OR with-
in the primary tumour. As well many of those patients whose
disease initially responds to tamoxifen, progress while still under
treatment having acquired resistance and this occurs despite
continued expression of OR. Thus suggesting other components
of the oestrogen signalling pathway may be altered. Recent obser-
vations using laboratory models (Hall and McDonnell, 1999; Lanz
et al, 1999; McKenna et al, 1999; Montano et al, 1999) have
demonstrated that altered levels of OR isoforms and/or alteration
of expression of coactivators and corepressors can deregulate
oestrogen and antioestrogen activity in target cells, suggesting
the hypothesis that altered levels of OR isoforms and/or coregu-
lators in vivo could be a mechanism of tamoxifen resistance.
Previously we have demonstrated that the relative expression of
ORa/ORb as well as the relative expression of some OR coactiva-
tors to corepressors is signiﬁcantly altered during breast
tumourigenesis in vivo (Leygue et al, 1998; Murphy et al,
2000). Furthermore, since these alterations parallel the marked
changes in oestrogen action that accompany breast tumourigen-
esis, they may have a role in this process. To explore the
hypothesis that such changes could underlie de novo tamoxifen
resistance in vivo, the expression of OR isoforms, two known
coactivators (steroid receptor RNA activator (SRA), (Lanz et al,
1999) and ampliﬁed in breast cancer-1 (AIB1) (Anzick et al,
1997)) and one corepressor (repressor of oestrogen receptor activ-
ity, repressor of oestrogen receptor activity (ROA) (Montano et
al, 1999)) of OR activity have been investigated in primary breast
tumours from node negative patients whose tumours were OR
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sion while on adjuvant tamoxifen therapy.
MATERIALS AND METHODS
Human breast tumours
All breast tumour cases used for this study were selected from the
NCIC-Manitoba Breast Tumour Bank (Winnipeg, Manitoba, Cana-
da). As previously described (Hiller et al, 1996), tissues are accrued
to the Bank from cases at multiple centres within Manitoba,
rapidly collected and processed to create matched formalin-ﬁxed-
embedded and frozen tissue blocks for each case with the mirror
image surfaces oriented by coloured inks. The histology of every
sample in the Bank is uniformly interpreted by a pathologist in
Hematoxylin/Eosin (H&E) stained sections from the face of the
parafﬁn tissue block. This information is available in a computer-
ized database along with relevant pathological and clinical
information and was used as a guide for selection of speciﬁc paraf-
ﬁn and frozen blocks from cases for this study. For each case,
interpretations included an estimate of the cellular composition
(including the percentage of invasive epithelial tumour cells and
stroma), tumour type and tumour grade (Nottingham score). Ster-
oid receptor status was determined for all cases by ligand binding
assay performed on an adjacent portion of tumour tissue. Tumours
with oestrogen receptor levels above 3 fmol mg
71 of total protein
were considered OR positive.
To identify cases that responded divergently to tamoxifen, review
of approximately 1000 consecutive cases was undertaken to identify
cases that were OR positive, node negative and that had been treated
with adjuvant tamoxifen following surgery +/7 local radiation.
From these the ﬁrst cohort of 27 cases was selected to include a
subset (n=13) that had shown progression of disease (either died
or alive with recurrent disease, referred to as tamoxifen resistant
cases) and a similar control subset (n=14) speciﬁcally selected to
comprise cases with similar lengths of follow-up, OR status, tumour
grade and tumour histology, but that had shown no progression of
disease (referred to as tamoxifen sensitive cases). The tumour char-
acteristics were: (1) ‘Tam Sensitive’ group median OR was
60.5 fmol mg
71 protein (range 6–146 fmol mg
71 protein), median
PR was 32 fmol mg
71 protein (range 8–216 fmol mg
71 protein);
median grade was ﬁve (range 4–8); median age at biopsy was 69
years (range 35–87 years); median follow-up time was 56 months
(range 18–79); (2) ‘Tam Resistant’ group median OR was
57 fmol mg
71 protein (range 4–136 fmol mg
71 protein); median
PR was 14 fmol mg
71 protein (range 4–288 fmol mg
71 protein);
median grade was six (range 4–9); median age at biopsy was 67
years (range 49–83 years); median follow-up time was 56 months
(range 9–85).
For the RNA studies, frozen tissue corresponding to the blocks for
several of the ﬁrst cohort of older cases used above, were not avail-
able. Therefore, after further review of the tumour bank as described
above, a second study cohort was selected that also had frozen tissue
available. The relevant patient/tumour characteristics were similar to
the above cohort, although the follow-up time was shorter: (1) ‘Tam
Sensitive’ group (n=16) median OR was 37.5 fmol mg
71 protein
(range 4.4–146 fmol mg
71 protein), median PR was 44 fmol mg
71
protein (range 13.1–216 fmol mg
71 protein); median grade was six
(range 4–9); median age at biopsy was 72 years (range 47–87
years); median follow-up time was 39 months (range 13–76); (2)
‘Tam Resistant’ group (n=16) median OR was 21.5 fmol mg
71
protein (range 5.6–107 fmol mg
71 protein); median PR was
14.3 fmol mg
71 protein (range 7.8–288 fmol mg
71 protein);
median grade was six (range 4–9); median age at biopsy was 71
years (range 60–89 years); median follow-up time was 34 months
(range 9–63).
Immunohistochemistry
Immunohistochemistry was performed on serial 5 mm sections
from a representative, formalin ﬁxed parafﬁn embedded archival
tissue block from each tumour. Immunohistochemical staining
for ORb was performed using two different primary antibodies.
IgYERB503 (a gift from Dr Jan-Ake Gustafson) detects total ORb
isoforms (Horvath et al, 2001; Saji et al, 2000) and GC17 (a gift
from Dr Shuk-Mei Ho) detects only the full-length ORb (Leav et
al, 2001). The GC17 polyclonal antibody was raised in rabbits
against a peptide sequence in the F domain of the human OR-b
receptor (amino acids 449 to 465) and its speciﬁcity validated
previously (Leav et al, 2001). The epitope to which the IgYERB503
antibody is directed is not known, but this polyclonal chicken anti-
body was raised to an ORb recombinant protein which was
disrupted in the ligand binding domain by insertion of 18 addi-
tional amino acids, but was subsequently shown to also recognise
the full-length non-inserted ORb protein (Saji et al, 2000). Antibo-
dies were applied using an automated tissue immunostainer
(Discovery module, Ventana Medical Systems, Phoenix, AZ,
USA), DAB immunohistochemistry kit and bulk reagents that were
supplied by the manufacturer. Brieﬂy, the Discovery staining
protocol was set to ‘Standard Cell Conditioning’ procedure,
followed by 12 h incubation with primary antibody and 32 min
incubation with secondary antibody. Concentrations of primary
antibodies initially applied to the Ventana instrument were
1:200 for IgYERB503 and 1:50 for GC17, which translates into
ﬁnal concentrations of 1:600 and 1:150 after a 1:3 dilution with
buffer dispensed onto the slide with the primary antibody. Levels
of nuclear ORb expression were scored semi-quantitatively, under
the light microscope. Scores were obtained by estimating average
signal intensity (on a scale of 0–300) and the proportion of
epithelial cells showing a positive signal (0, none; 0.1, less than
one tenth; 0.5, less than one half; 1.0 greater than one half). The
intensity and proportion scores were then multiplied to give an
overall IHC-score. Cases with a score lower than or equal to 100
were considered negative or weakly positive, whereas tumours with
scores higher than 100 were classiﬁed as positive for ORb expres-
sion (Al-Haddad et al, 1999).
RNA Extraction and RT–PCR conditions
Total RNA was extracted from 20 mm frozen tissue sections (20
sections per tumour) using Trizol
TM reagent (Life Technologies,
NY, USA) according to the manufacturer’s instructions and quan-
tiﬁed spectrophotometrically. One mg of total RNA was reverse
transcribed in a ﬁnal volume of 25 ml as previously described
(Leygue et al, 1996).
Primers and PCR conditions
Coregulators The primers used were: SRAcoreU primer (5'-
AGGAACGCGGCTGGAACGA-3'; sense; positions 35–53,
Genbank accession number AF092038) and SRAcoreL primer (5'-
AGTCTGGGGAACCGAGGAT-3'; antisense; position 696–678,
Genbank accession number AF092038); AIB1-U primer (5'-
ATACTTGCTGGATGGTGGACT-3'; sense; positions 110–130,
Genbank accession number AF012108) and AIB1-L primer (5'-
TCCTTGCTCTTTTATTTG ACG-3'; antisense; positions 458–
438, Genbank accession number AF012108); ROA-U primer (5'-
CGAAAAATCTCCTCCCCTACA-3'; sense; positions 385–405,
Genbank accession number AF150962) and ROA-L primer (5'-
CCTGCTTTGCTTTTTCTACCA-3'; antisense; positions 781–761,
Genbank accession number AF150962).
Radioactive PCR ampliﬁcations for SRA were performed and
PCR products analysed as previously described (Leygue et al,
1999b) with minor modiﬁcations. Brieﬂy, 1 ml of reverse transcrip-
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British Journal of Cancer (2002) 87(12), 1411–1416 ã 2002 Cancer Research UKtion mixture was ampliﬁed in a ﬁnal volume of 15 ml, in the
presence of 1.5 mCi of (a-
32P) dCTP (3000 Ci mmol
71), 4 ng ml
71
of each primer and 0.3 unit of Taq DNA polymerase (Gibco BRL,
Grand Island, NY, USA). For SRA each PCR consisted of 30 cycles
(30 s at 948C, 30 s at 608C and 30 s at 728C). PCR products were
then separated on 6% polyacrylamide gels containing 7 M urea.
Following electrophoresis, the gels were dried and exposed 2 h to
a Molecular Imager
TM-FX Imaging screen (Bio-Rad, Hercules,
CA, USA).
PCR ampliﬁcations for AIB1 and ROA were performed and PCR
products analysed as previously described (Leygue et al, 1996) with
minor modiﬁcations. Brieﬂy, 1 ml of reverse transcription mixture
was ampliﬁed in a ﬁnal volume of 20 ml, in the presence of
4n gml
71 of each primer and 0.3 unit of Taq DNA polymerase
(Gibco BRL, Grand Island, NY, USA). For AIB1, each PCR
consisted of 30 cycles (30 s at 948C, 30 s at 558C and 30 s at
728C). For ROA each PCR consisted of 30 cycles (30 s at 948C,
30 s at 578C and 30 s at 728C). PCR products were then separated
on agarose gels stained with ethidium bromide as previously
described (Leygue et al, 1996).
Primers for OR isoforms
ORa-U primer (5'-TGTGCAATGACTATGCTTCA-3'; sense;
located in ORa 792–811) and ORa-L primer (5'-GCTCTT-
CCTCCTGTTTTTA-3'; antisense; located in ORa 940–922).
Nucleotide positions given correspond to published sequences of
the human ORa cDNA (Green et al, 1986). PCR ampliﬁcations
were performed and PCR products analysed as previously described
with minor modiﬁcations (Dotzlaw et al, 1997). Brieﬂy, 1 mlo f
reverse transcription mixture was ampliﬁed in a ﬁnal volume of
15 ml, in the presence of 1 mCi (a-
32P) dCTP (3000 Ci mmol
71),
2n gml
71 of ORa-U/ORa-L and 0.3 unit of Taq DNA polymerase
(Gibco BRL, Grand Island, NY, USA). Each PCR consisted of 30
cycles (30 s at 948C, 30 s at 608C and 30 s at 728C).
A previously validated triple primer assay was used to determine
the relative expression of ORb1 and its variant isoforms ORb2 and
ORb5 (Leygue et al, 1999a). Brieﬂy, 1 ml of reverse transcription
mixture was ampliﬁed in a ﬁnal volume of 15 ml, in the presence
of 1 mCi of (a-
32P) dCTP (3000 Ci mmol
71), 4 ng ml
71 of each
primer (ORb1U, ORb1L and ORb2L) and 0.3 unit of Taq DNA
polymerase (Gibco BRL, Grand Island, NY, USA).
All OR PCRs consisted of 30 cycles (30 s at 948C, 30 s at 608C,
and 30 s at 728C). PCR products were then separated on 6% poly-
acrylamide gels containing 7 M urea. Following electrophoresis, the
gels were dried and autoradiographed. Three independent PCRs
were performed.
Quantiﬁcation of SRA and OR RNA expression Exposed
screens were scanned using a Molecular Imager
TM-FX (Bio-Rad,
Hercules, CA, USA) and the intensity of the signal corresponding
to SRA or the appropriate OR isoform PCR fragments was
measured using Quantity One
TM software (Bio-Rad, Hercules,
CA, USA). Three independent PCRs were performed. In order to
control for variations between experiments, a value of 1 was arbi-
trarily assigned to the signal of one particular tumour measured in
each set of PCR experiments (always the same tumour) and all
signals were expressed relative to this signal. Levels of SRA was
expressed relative to ROA (SRA/ROA), AIB1 (SRA/AIB1) or ORa
(SRA/ORa) in each individual tumour sample. Levels of ORb
isoforms were expressed relative to other ORb isoforms shown
under statistical analysis and as previously described (Leygue et
al, 1999a).
Quantiﬁcation of the relative expression of the deleted SRA
variant RNA It has previously been shown that the coampliﬁca-
tion of a full-length and a deleted variant SRA (SRA-Del) cDNA
resulted in the ampliﬁcation of two PCR products, the relative
signal intensity of which provided a reliable measurement of the
relative expression of the deleted variant (Leygue et al, 1999b).
For each sample, the signal corresponding to the SRA-Del was
measured using Quantity One
TM software (Bio-Rad, Hercules,
CA, USA) and expressed as a percentage of the corresponding core
SRA signal. For each case, three independent assays were
performed and the mean determined.
Quantiﬁcation of ROA and AIB1 RNA expression Following
analysis of PCR products on prestained agarose gels, signals were
quantiﬁed by scanning using MultiAnalyst
TM (Bio-Rad, Hercules,
CA, USA). At least, three independent PCRs were performed. A
value of 1 was arbitrarily assigned to the ROA or AIB1 signal of
one particular tumour and is the same tumour as described above
and all signals were expressed relative to this signal. Levels of AIB1
were expressed relative to ROA (AIB1/ROA) and ORa (AIB1/
ORa), and levels of ROA were expressed relative to ORa (ROA/
ORa).
Statistical analysis Differences between tamoxifen sensitive and
tamoxifen resistant cases were tested using the Mann–Whitney
rank sum test, two-tailed. Potential differences in expression
between the two groups with respect to each ORb isoform RNA
relative to other ORb isoform RNA expression (e.g. log ORb1/total
ORb; log ORb2/total ORb; log ORb5/total ORb, as previously
described (Leygue et al, 1999a)), and the relative expressions of
coregulators (i.e. logAIB1/ROA; logSRA/ROA; logSRA/AIB1;
logAIB1/ORa; logSRA/ORa; logROA/ORa) were determined.
Tumours were classiﬁed as low (scores between 0 and 100) and
high (150–300) ORb expressors, and differences between tamoxi-
fen sensitive and tamoxifen resistant cases were tested using
Fisher’s exact test. Correlation between ORb protein expression
(IHC-score) and tumour characteristics was tested by calculation
of the Spearman coefﬁcient r.
RESULTS
Expression of ORb protein in primary human breast
tumours from patients who later progressed on tamoxifen
treatment or showed no progression on tamoxifen
treatment
ORb protein was determined immunohistochemically on adjacent
sections from each tumour, using two different antibodies. GC-
17 is an antibody recognizing an epitope in the C-terminus of
full-length ORb1 (Leav et al, 2001). Normal breast tissue was used
as a positive control and is shown in Figure 1A. Examples of stain-
ing in human breast tumour sections are shown in Figure 1B–D.
Some tumour sections showed no (Figure 1B, full-length ORb
score=0) or low (Figure 1C, full-length ORb score=100), while
others showed strong full-length ORb signals (Figure 1D, wild-type
ORb score=300). Tumours were classiﬁed as low (scores between 0
and 100) and high (150–300) full-length ORb protein expressors,
and differences between tamoxifen sensitive and resistant tumours
determined by Fisher’s exact test. No signiﬁcant differences were
found.
IgYERbeta503 is an antibody that recognises ligand binding and
non-ligand binding ORb protein isoforms (Horvath et al, 2001;
Saji et al, 2000) and which we refer to as total ORb protein.
Normal breast tissue was used as a positive control and is shown
in Figure 2A. Examples of staining with this antibody in human
breast tumour sections are shown in Figure 2B–D. Some sections
showed no (Figure 2B, total ORb score=0) or low (Figure 2C, total
ORb score=100) total ORb expression whereas others had strong
total ORb protein signal (Figure 2D, total ORb score=300).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1411–1416Tumours were classiﬁed as low and high total ORb protein expres-
sors, and there was a statistically signiﬁcant difference in high total
ORb protein between the Tamoxifen sensitive and resistant groups
(Fisher’s exact test, P=0.046). High total ORb protein expressors
were more frequently observed in tamoxifen sensitive tumours than
resistant tumours.
Correlation between ORb protein expression and tumour char-
acteristics was tested by calculation of the Spearman coefﬁcient. A
positive correlation between ORb1 (GC17) protein and progester-
one receptor (PR) levels (Spearman r=0.44, P=0.022) was found
when each was examined as continuous variables. When tumours
were divided into PR+ (410 fmol mg
71 protein) or PR7
(410 fmol mg
71 protein) groups there was a signiﬁcantly higher
level of ORb1 (GC17) protein in PR+ tumours compared to
PR7 tumours (Mann–Whitney test, P=0.0268; median for PR+
tumours=55, range 5–150 and median for PR7 tumours=10,
range 0–75). As well, there was also a signiﬁcantly higher level
of total ORb (IgY503) protein in PR+ tumours compared to
PR7 tumours (Mann–Whitney test, P=0.0085; median for PR+
tumours=125, range 25–270 and median for PR7 tumours=50
range 0–100).
Relative expression of ORb isoform RNA in primary human
breast tumours from patients who later progressed on
tamoxifen treatment or showed no progression on adjuvant
tamoxifen To determine if the differences described above in
ORb protein expression were correlated with differences in
ORb variant isoform RNA expression, we compared the relative
expression of ORb variant RNA to full-length ORb RNA in the
tamoxifen sensitive and resistant groups. Unfortunately, frozen
tissue samples corresponding to many of the parafﬁn blocks
from patients in the cohort used for immunohistochemistry were
not available. Therefore additional cases selected were selected
from the tumourbank as described in Materials and Methods.
Using previously validated assays (Leygue et al, 1998; 1999a)
the relative expression of ORb2, ORb5 and full-length ORb1
RNA in the tamoxifen sensitive and resistant groups was not
signiﬁcantly different.
Relative expression of coregulators in primary human breast
tumours from patients who later progressed on tamoxifen
treatment or showed no progression on tamoxifen treat-
ment To address the hypothesis that altered relative expression
of steroid receptor coactivators and corepressors could underlie
altered tamoxifen sensitivity in human breast tumours, and since
we previously showed that the relative expression of two coactiva-
tors (SRA and AIB1) to a corepressor (ROA) is altered in OR+
breast tumours compared their adjacent normal breast tissue, we
chose these coregulators to study. They were measured by RT–
PCR in the above tumour cohorts. SRA, AIB1, and ROA mRNAs
were detectable in most samples, even though their level of expres-
sion differed from one sample to another. Consistent with our
previous results (Leygue et al, 1999b), an additional fragment,
migrating at an apparent size of 459 bp was also observed in most
tumours when using SRA speciﬁc primers. Sequencing analysis
revealed that this band corresponded to a variant form of SRA
(referred to as SRA-Del) deleted in 203 bp between positions 155
and 357 (positions given correspond to Genbank accession number
AF092038). There were no signiﬁcant differences between the
tamoxifen sensitive and the de novo tamoxifen resistant breast
cancers in the relative expression of any of the coactivators to core-
pressor RNA, or in the relative expression of SRA/AIB1 RNA, or in
expression of any of these coregulator RNAs relative to ORa or
total ORb RNA expression. As well, there was no signiﬁcant differ-
ence in the relative expression of variant SRA/full-length SRA
between the groups either.
Tumour characteristics No statistically signiﬁcant differences
were found between the tamoxifen sensitive and tamoxifen resis-
tant cohorts in any of the tumour characteristics described in the
Materials and Methods section except for PR. PR levels were statis-
tically signiﬁcantly different (P=0.044) between the two groups
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Figure 1 Examples of immunohistochemistry using the GC-17 antibody
which only recognises the full-length ORb1: (A) normal human breast tis-
sue; (B)O R b1 negative human breast tumour, H-score=0; (C)O R b1 low
expressing human breast tumour, H-score=100; (D)O R b1 high expressing
human breast tumour, H-score=150.
Figure 2 Examples of immunohistochemistry using the IgYERb503 anti-
body which recognises most ORb isoforms: (A) normal human breast tis-
sue; (B)O R b negative human breast tumour, H-score=25; (C)O R b low
expressing human breast tumour, H-score=100; (D)O R b high expressing
human breast tumour, H-score=225.
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higher (median PR was 32 fmol mg
71 protein; range 8–
216 fmol mg
71 protein) in the tamoxifen ‘sensitive’ group
compared to the tamoxifen ‘de novo resistant’ group (median PR
was 14 fmol mg
71 protein; range 4–288 fmol mg
71 protein). This
was a consistent ﬁnding in both selected cohorts (that used for
immunohistochemistry and that used for the RNA study), and
provides strong support for differences in oestrogen signalling
pathways in these two groups since PR is a marker of OR signal
transduction (Horwitz et al, 1975; Osborne, 1998a).
DISCUSSION
We and others have shown that the relative expression of ORa and
ORb is signiﬁcantly altered during breast tumourigenesis (Leygue
et al, 1998; Roger et al, 2001), and a similar mechanism has been
proposed to underlie tamoxifen resistance in breast cancers (Paech
et al, 1997). The current study shows no signiﬁcant differences in
expression of full-length ORb (ORb1) between tamoxifen sensitive
and resistant tumours. Interestingly, in this small cohort of
tumours when total ORb expression was examined, there were
signiﬁcantly more high total ORb expressors in the tamoxifen
‘sensitive’ compared to the ‘resistant’ group. The data suggest the
possibility that increased and altered ORb isoform protein expres-
sion may have a role in de novo tamoxifen resistance, or at least
together with other parameters may provide better markers of
endocrine sensitivity. The increased expression of ORb proteins
in the tamoxifen sensitive group is also consistent with recently
published data where patients with ORb positive tumours (deter-
mined using an antibody to an N-terminal epitope of the ORb
protein, and deﬁned as nuclear staining in 410% of cancer cells)
had a signiﬁcantly better overall survival than patients with ORb
negative tumours while receiving adjuvant tamoxifen therapy
(Mann et al, 2001). Both these latter data and those presented
currently in this manuscript are in contrast to data showing
increased ORb RNA expression in tamoxifen resistant tumours
versus tamoxifen sensitive tumours previously published (Speirs
et al, 1999). Together these studies suggest that the ORb status
and the nature of ORb isoforms together with ORa status in
human breast cancers may be important biomarkers of endocrine
sensitivity, and warrants further study, in larger, prospectively gath-
ered cohorts. The association of increased ORb isoform expression
with tamoxifen sensitivity, suggests a possible mechanistic role, and
one possible mechanism may be suggested by several publications
which have shown that ORb isoforms have a modulatory effect
on ORa, both in normal tissues (Weihua et al, 2000) as well as
in cell culture models (Ogawa et al, 1998; Hall and McDonnell,
1999).
The potential difference between tamoxifen sensitive and resis-
tant groups with respect to ORb-like proteins, was not correlated
with differences in the relative expression of full-length ORb and
two known variants ORb2 and ORb5 at the RNA level between
the tamoxifen ‘sensitive’ versus the tamoxifen ‘resistant’ groups,
however. This may be due to differential regulation of protein
versus RNA level or the likelihood that there are other potential
ORb isoforms (known and unknown) expressed in breast tissues
in addition to ORb1, ORb2 and ORb5 (Lu et al, 1998; Fuqua et
al, 1999), whose cognate proteins would be detected by the anti-
body but not measured in the triple primer RT–PCR assay.
Another mechanism for differential tamoxifen sensitivity in OR+
breast tumours could be altered coregulator expression. Although
the relative expression of OR coregulators SRA, AIB1 and ROA
is altered between normal breast and OR+ breast tumours, there
were no signiﬁcant differences in the ratios of any of the coactiva-
tors/corepressors or any of the ratios of these coregulators to ORa
RNA levels between primary breast tumours from patients who
were later found to be disease free (sensitive) or have disease
progression (resistant) while on adjuvant tamoxifen treatment.
These data suggest that altered relative expression of these coregu-
lators is unlikely to be a marker of tamoxifen sensitivity in OR+,
node negative, primary breast tumours, and unlikely to have a
functional role in de novo tamoxifen resistance. Although SRA is
functional as an RNA molecule, ROA and AIB1 are functional as
proteins. Furthermore, other factors can affect protein activity for
example phosphorylation in the case of AIB1 (Mora and Brown,
2000) or sequestration by other proteins such as prothymosin-
alpha in the case of ROA (Martini et al, 2000). Our studies do
not exclude differences at the protein and/or activity levels of
ROA and AIB1 being involved in de novo tamoxifen resistance,
nor do they exclude altered expression of these factors having a
role in acquired tamoxifen resistance (Lavinsky et al, 1998). Alto-
gether, there is little evidence for altered coregulators expression
in breast tumours that are de novo tamoxifen resistant. However,
our data provide preliminary evidence that the expression of
ORb protein isoforms may differ in primary tumours of breast
cancer patients who prove to have differential sensitivity to tamox-
ifen therapy. As well our data support distinct differences in the
OR signalling pathways between these two groups of patients since
the expression of a known oestrogen responsive gene PR is signiﬁ-
cantly different between the two groups, the precise mechanisms
underlying these differences remain to be elucidated.
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